Skip to main content

Thomas G. Gross, MD

Edit Profile

Thomas G. Gross, MD

Edit Profile

Phone Number

Locations

About Thomas G. Gross, MD

Thomas Gross, MD, PhD, is a pediatric hematologist and oncologist at Phoenix Children's. Dr. Gross provides specialized care and treatment options for children and adolescents with leukemia and lymphoma. He has more than 30 years of experience in the field of pediatric hematology and oncology.

Dr. Gross graduated with his bachelor's degree in biochemistry from the University of Nebraska in Lincoln, Nebraska. He earned his medical and doctorate degrees from the University of Nebraska Medical Center in Omaha, Nebraska, where he also completed his pediatric residency. Dr. Gross pursued fellowship training in pediatric hematology/oncology at the University of Minnesota Hospital and Clinics in Minneapolis.

...Read more

Thomas Gross, MD, PhD, is a pediatric hematologist and oncologist at Phoenix Children's. Dr. Gross provides specialized care and treatment options for children and adolescents with leukemia and lymphoma. He has more than 30 years of experience in the field of pediatric hematology and oncology.

Dr. Gross graduated with his bachelor's degree in biochemistry from the University of Nebraska in Lincoln, Nebraska. He earned his medical and doctorate degrees from the University of Nebraska Medical Center in Omaha, Nebraska, where he also completed his pediatric residency. Dr. Gross pursued fellowship training in pediatric hematology/oncology at the University of Minnesota Hospital and Clinics in Minneapolis.

Research by Dr. Gross has appeared in notable peer-reviewed publications including The New England Journal of Medicine, The Lancet Oncology, the Journal of Clinical Oncology and the American Journal of Transplantation. He previously served as deputy editor of the journal Pediatric Blood and Cancer. In addition, Dr. Gross has presented at national and international events including annual conferences of the American Society of Pediatric Hematology/Oncology and the Society of Pediatric Liver Transplantation. He was recently an invited keynote speaker at the International Congress for Malignant Lymphoma and the Congress of the International Society of Pediatric Oncology.

Dr. Gross is board certified in general pediatrics and pediatric hematology/oncology. He is a member of the American Society of Clinical Oncology, the American Society of Hematology, the American Society of Pediatric Hematology/Oncology, the Histiocyte Society and the Society of International Pediatric Oncology. Dr. Gross has served in multiple leadership positions with both the Children's Oncology Group and the Center for Global Health at the National Cancer Institute.

Working to provide the best care possible for his patients and their families, Dr. Gross is proud to be a source of information and advice. He believes that working as a team results in the best decisions and outcomes for his patients.

In his free time, Dr. Gross enjoys cycling, fishing and reading.

Read less

+Education & Training

Board Certification

Pediatrics, Subspecialty-Pediatric Hematology/Oncology; American Board of Pediatrics

Medical School / Education

University of Nebraska Medical Center, Omaha, NE

Residency

(Pediatrics) University of Nebraska Medical Center, Omaha, NE

Fellowship

(Hematology/Oncology) University of Minnesota Hospital and Clinics, Minneapolis, MN

+Academic and Professional Affiliations

Professional Affiliations

Member, American Society of Clinical Oncology

Member, American Society of Hematology

Member, American Society of Pediatric Hematology/Oncology

Member, Histiocyte Society

Member, Society of International Pediatric Oncology

+Research & Publications

Publications

Minard-Colin V, Auperin A, Pillon M, Burke A, Barkauskas D, Wheatley K, Delgado RF, Alexander S, Uyttebroeck A, Bollard C, Zsiros J, Csoka M, Kazanowska B, Chiang A, Patte C,*Gross TG, *on behalf of the European Intergroup for Childhood Non-Hodgkin's lymphoma (EICNHL) and the Children's Oncology Group (COG). Rituximab in children and adolescents with high-risk mature B-cell non-Hodgkin's lymphoma/leukaemia: Final results of the Inter-B-NHL ritux 2010 trial. New Engl J Med 382::2207-19, 2020.

Atun R*, Bhakta N, Denburg A, Frazier AL, Friedrich P, Gupta S, Lam CG, Ward Z, Yeh J, Allemani C, Coleman M, di Carlo V, Loucaides E, Fitchett E, Girardi F, Horton S, Steliarova-Foucher E, Sullivan R, Aitken J, Banavali S, Binagwaho A, Alcasabas P, Antillon F, Arora R, Barr RD, Bouffet E, Challinor J, Fuentes S, Gross T, Hagander L, Hoffman R, Herrera C, Kutluk T, Marcus K, Moreira C, Pritchard-Jones K, Ramirez Lorna Renner O, Robison LL, Shalkov J, Sung L, Yeoh Y, Rodriguez-Galindo C*. Lancet Oncology Commission on Sustainable Care for Children with Cancer. Lancet Oncol. 21:e185-e224, 2020.

Rodriguez-Galindo C, Friedrich P, Alcasabas P, Antillon F, Castillo L, Israels T, Sharif M, Jeha S, Sullivan M, Banavali B, Chong QT, Pui C-H, Barr R, Gross T. Towards the Cure of All Children with Cancer: Pediatric Oncology as a Global Challenge, J Clin Oncol 33:3065-73, 2015.

Gross TG, Orjeula MA, Park JR, Perkins SL, Lynch JC, Cairo MS, Smith LM, Hayashi RJ. Low-dose chemotherapy and rituximab for post-transplant lymphoproliferative disease (PTLD): Children's Oncology Group report. Am J Transplant. 12:3069-3075, 2012.

Share this page